DISPATCHES FROM INTERPHEX

Kemwell Talks Expansion and Approvals in India and the US

Related tags Economics India

At this year’s Interphex, Kemwell Biopharma spoke to Outsourcing-Pharma.com about recent expansions in both India and the US.

Kemwell’s Director of Corporate Development Christian Ahlmark, spoke about the FDA approval at its manufacturing plant in Bangalore, India as well as the biologics facility - also in Bangalore – that recently opened its doors.

Kemwell recently announced 1500 sq ft of analytical lab space had been added​ in response to a contract by a major manufacturer.

However, it is not just India where Kemwell has been expanding. Ahlmark said the company was expanding its “lab footprint”​ on the East Coast in order to offer its current customers formulation development, expertise, analyticals and project management services.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers

Follow us

Products

View more

Webinars